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S U M M A R Y
Objectives: To investigate the extent to which Greek patients with West Nile virus neuroinvasive disease
(WNND) recovered from the initial infection in 2010, when a West Nile virus (WNV) lineage 2 outbreak
took place.
Methods: Twenty-two patients with WNND were examined 16 months after the onset of symptoms. The
physical and mental function of the 22 survivors was evaluated.
Results: A considerable persistent morbidity and long length of time to recovery was observed. The most
common symptoms were anorexia (77.3%) and muscle weakness (72.7%), followed by memory
impairment (36.4%) and depression (22.7%). Older age was correlated with memory impairment, muscle
weakness, and permanent damage. A complete recovery was seen in 7/22 (31.8%) patients, while three
patients presented permanent damage. The critical time-point was 1 year after the onset of symptoms;
at that time the patient’s health status was either highly improved or had deteriorated irreversibly.
Conclusions: WNND is associated with considerable short- and long-term morbidity and mortality.
Lineage 2 strains need further scientiﬁc attention. Public health measures are needed to prevent the
infection, especially in the elderly with underlying diseases.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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West Nile virus (WNV) is a mosquito-borne ﬂavivirus that was
initially restricted to Africa, but sporadic cases and outbreaks now
occur almost worldwide. Although the vast majority of WNV
infections are asymptomatic or mild, approximately 1% of cases are
characterized by virus entry into the central nervous system and
infection of neural cells, resulting in neuroinvasive disease
(WNND), which presents mainly as encephalitis, meningitis,
meningoencephalitis, or acute ﬂaccid paralysis.1 Older age and
immunosuppression are highly correlated with WNV neuroinva-
siveness.
A large outbreak of WNV infections occurred in 2010 in Greece,
a country from which the disease has not previously been
reported.2 Apart from the subclinical and mild cases, 197 patients
presented with WNND, and 33 of them (17%) died. Cases were
observed mainly in Central Macedonia, Northern Greece, where
the incidence of WNND was 15 per 100 000 population, with the
highest incidences in the districts of Pella and Imathia (28.26 and
27.06 per 100 000 population, respectively).3 A few days after
the outbreak started, WNV lineage 2 (strain Nea Santa/2010/
Greece) was detected in mosquitoes collected in regions where
human cases had been observed.4 Identical strains were* Corresponding author. Tel.: +30 2310 999006; fax: +30 2310 999151.
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mosquitoes, wild birds, and sentinel chickens.5–7 It was
concluded that the outbreak was caused by this speciﬁc strain,
which is genetically similar to that isolated in a dead goshawk
in Hungary in 2004, presenting 44 mutations, one of them
resulting in the amino acid substitution H249P in the NS3
protein.8 This speciﬁc mutation has previously been associated
with increased replication capacity in corvids in WNV lineage 1
strains.9 Although many factors are implicated in the patho-
genesis of WNV, this speciﬁc mutation might explain the
difference in incidence and fatality rates between Greece and
Hungary, where a yearly average of 6 WNND cases were
diagnosed between 2003 and 2007, and 14 cases in 2008.10
Although a full recovery is seen in most patients with
meningitis, the prognosis is much worse in encephalitis and
ﬂaccid paralysis cases, which are characterized by high fatality
rates. Signiﬁcant long-term morbidity is seen among survivors
who experience neurological deﬁcits, lasting from months to
years after infection, including fatigue, muscle weakness,
headache, persistent movement disorders, memory loss, and
depression.11–17 Most, if not all, post WNND studies have been
conducted in areas where WNV lineage 1 strains have been
detected (e.g., North America, Israel). The aim of the present
study was to investigate and describe the extent to which
patients with neurologic manifestations recover from their initial
infection in Greece, where all sequences obtained during 2010–
2011 belonged to lineage 2.ses. Published by Elsevier Ltd. All rights reserved.
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The present prospective study was performed in Giannitsa
Hospital in the prefecture of Pella, where the highest incidence of
WNND was observed in 2010 (28.26 per 100 000 population).3
During August through September 2010, 31 patients with WNND
were hospitalized. The laboratory diagnosis was made by detection
of WNV IgM and IgG antibodies using an ELISA (WNV IgM capture
DxSelect and WNV IgG DxSelect, respectively; Focus Diagnostics
Inc., Cypress, CA, USA). Eight (25.8%) patients died while in
hospital; by 1 year, an additional patient had died. The 22 survivors
(11 male and 11 female) were asked to attend for an evaluation of
their physical and mental function; all agreed to be tested
(response rate 100%), and oral consent was obtained. The interview
and re-evaluation were performed by one physician (AA) at 16 (
1) months after symptom onset. Recovery was deﬁned as a complete
return to baseline function, i.e. that prior to infection. A statistical
analysis was performed using binary logistic regression with the IBM
SPSS 19 package. Odds ratios (OR) and 95% conﬁdence intervals (95%
CIs) were obtained and statistical signiﬁcance was deﬁned as a two-
tailed p-value of less than 0.05.
3. Results and discussion
Twenty-two WNND patients (11 male and 11 female) were
followed-up at 16 ( 1) months after symptom onset. Most of them
(n = 20) were patients with encephalitis; two (one male and one
female) had meningoencephalitis (cases 3 and 19 in Table 1). The
median age of the patients was 70 years (range 23–87 years), with
males being signiﬁcantly younger than females (p < 0.05) (Table 1).
Most patients (17/22, 77.3%) had an underlying disease: 15 had
hypertension and ﬁve had diabetes mellitus. The mean hospitaliza-
tion time was 8.09 days (range 5–21 days) and differed signiﬁcantly
between male and female patients. Persistence of WNV IgM
antibodies was observed in one male patient at 220 days after the
onset of symptoms;18 these were not detectable at the 18-month
follow-up.
A brief description of the main symptoms, underlying diseases
and sequelae in each of the 22 cases is given in Table 2. The most
common persisting symptoms were anorexia (77.3%), leading to
weight loss (up to 30 kg), and muscle weakness (72.7%), followed
by memory impairment (36.4%) and depression (22.7%) (Table 1).
Patients with depression were evaluated and followed-up by a
psychiatrist. A complete recovery was seen in 7/22 (31.8%) patients
and improvement in 12 patients, while three presented permanent
impairments. Although improvement was usually observed at 1–2
months after the onset of symptoms, the critical time-point for the
health status of the patient was at 1 year, when the patient’sTable 1
Demographic and clinical characteristics of study patients with West Nile virus neuroi
Variable Males (n = 11) Females (n 
Age, years, median (range) 42 (23–86) 71 (63–87) 
Underlying disease (%) 6 (54.5) 11 (100) 
Days in hospital, mean (range, SD) 6.27 (5–9, 1.34) 9.91 (5–21
Anorexia (%) 7 (63.6) 10 (90.9) 
Tremor (%) 4 (36.4) 0 (0) 
Muscle weakness (%) 6 (54.5) 10 (90.9) 
Dizziness (%) 1 (9.1) 3 (27.3) 
Intense sweating (%) 0 (0) 2 (18.2) 
Depression (%) 1 (9.1) 4 (36.4) 
Memory problems (%) 4 (36.4) 4 (36.4) 
Hearing loss (%) 2 (18.2) 1 (9.1) 
Permanent damage (%) 1 (9.1) 2 (18.2) 
Complete recovery (%) 6 (54.5) 1 (9.1) 
Months to recovery, mean (range) (n = 7) 4.3 (1–12) 8.4 (1–12)
OR, odds ratio (females:males); CI, conﬁdence interval; SD, standard deviation.
a OR males:females.condition was either highly improved or had deteriorated
irreversibly. One female patient (case 10) who had an underlying
disease was hospitalized six times during the 16-month period
(once in the intensive care unit), because of respiratory or urinary
infections. An additional female patient (case 3) visited the
hospital several times because of severe constipation (gut
paralysis); the symptom lasted for approximately 1.5 year, and
then the patient started to gain the lost weight (30 kg).
Male patients recovered earlier than females (p < 0.05), most
probably due to their younger age and the absence of predisposing
conditions in most of the male patients. Increased age was
correlated with the presence of underlying disease, memory
impairment, anorexia, sweating, muscle weakness, tremor, and
permanent damage (p < 0.05); in contrast, depression, dizziness,
and hearing loss were not age-dependent. The mean time needed
for complete recovery in the seven patients was 6.26 months, with
a trend of earlier recovery for the male patients (4.3 months vs. 8.4
months in females). With regard to the three patients who
presented permanent impairment (bedridden, dementia), they
were all older than 70 years (74, 86, and 87 years). Interestingly,
an 83-year-old female patient with underlying syndromes and
severe muscle weakness, started to recover 10 months after the
onset of disease, and her status was premorbid at the 16-month
follow-up.
WNV encephalitis is associated with considerable short-term
and long-term morbidity and mortality.19 The in-hospital fatality
rate of patients with WNND of the present study was 25.8%, which
is among the highest reported so far.15,20–22 The delayed clearance
of the virus correlates with frequent neurological sequelae. The
ﬁndings at the 16-month follow-up demonstrated a spectrum of
functional and strength outcomes, with a considerable persistent
morbidity, since more than half of the survivors had not returned
to their previous functional level. This is consistent with studies
from North America, where the responsible WNV strain belonged
to lineage 1.15
Anorexia and muscle weakness were the most common
persistent symptoms. Similarly, symptom duration of more than
3 months was observed for 48.7% of WNV encephalitis patients in
Denver, Colorado; muscle weakness, muscle pain, and headache
were the most frequently reported persistent symptoms.23 Two of
our patients required supplemental oxygen for 6 months.
Neuromuscular respiratory failure is the most severe manifesta-
tion of WNV poliomyelitis, and although successful extubation and
recovery can occur, respiratory involvement is associated with a
high fatality rate (>50%).19
Preexisting comorbid conditions play a signiﬁcant role in a
longer recovery.24 This was observed in the present study: ﬁve
of the seven recovered patients were relatively young (25–55nvasive disease
= 11) Total (n = 22) p-Value OR 95% CI
70 (23–87) 0.03 1.08 1.0–1.1
17 (77.3) 0.99 1.34 0
, 4.67) 8.09 (5–21, 3.84) 0.04 1.77 1.0–3.0
17 (77.3) 0.15 5.71 0.5–62.6
4 (18.2) 0.99 9.23a
16 (72.7) 0.08 8.33 0.7–89.4
4 (18.2) 0.29 3.75 0.3–43.3
2 (9.1) 0.15 5.71 0.5–62.6
5 (22.7) 0,15 5.71 0.5–62.6
8 (36.4) 1.0 1.00 0.1–5.6
3 (13.6) 0.54 0.45 0.03–5.8
3 (13.6) 0.54 2.22 0.1–28.8
7 (31.8) 0.04 12.00a 1.1–128.8
 6.26 (1–12) 0.31 1.48 0.6–3.2
Table 2
Main characteristics of the patients included in the study
Case No. Gender Age Co-morbidities Time in
hospital
Main symptoms during
convalescence
Time to recovery; sequelae
1 Female 65 Hypertension 9 days Weight loss (10 kg), respiratory
failure (supplemental oxygen for 6
months), permanent phrenic nerve
palsy, major depression
Not fully recovered; elevation of left
hemidiaphragm, major depression
2 Female 79 Hypertension 10 days Anorexia for 3 months, muscle
weakness, dizziness, intense sweating,
impaired memory
Not fully recovered; muscle weakness,
persistent dizziness, impaired memory
3 Female 70 Hypertension 11 days Anorexia for 1 year, weight loss
(>30 kg), bedridden for 8–10 months,
Guillain–Barre´–like quadriplegia for
1 year, muscle weakness, emotional
instability, major depression,
abdominal pain, severe constipation for
1.5 years
Not fully recovered; pulmonary
hypertension, muscle weakness, major
depression
4 Female 63 Hypertension, type II diabetes 8 days Muscle weakness, anorexia, sweating,
unregulated diabetes for 8 months,
depression
Not fully recovered; muscle weakness,
major depression
5 Female 74 Hypertension 10 days Weight loss, severe anorexia for 6
months, amnesia, lack of concentration,
muscle weakness of lower limbs,
bedridden
Permanent impairment; dementia,
bedridden
6 Female 83 Hypertension, heart failure 6 days Respiratory insufﬁciency –
supplemental oxygen (at home) for 6
months, anorexia for 3 months, weight
loss (10 kg), muscular weakness for 6
months, unable to walk (used walker
for 3 months), bad mood
10 months
7 Female 71 Parkinson’s disease 5 days Muscle weakness, use of wheelchair,
anorexia, weight loss (10 kg),
constipation, insomnia, bad mood for 1
year
Not fully recovered; muscle weakness
8 Female 87 Hypertension 15 days Weight loss, weakness, unable to walk
(initially required a walker, then
bedridden), impaired memory
Permanent impairment; bedridden,
dementia
9 Female 70 Hypertension thyroidectomy 9 days Weight loss (>10 kg), muscle weakness,
headache, fatigue, dizziness, bad mood,
depression, unable to walk for 1 month
(walker required)
Not fully recovered; headache,
dizziness, major depression
10 Female 72 Hypertension, breast cancer 21 days Headache, memory impairment,
hearing loss, muscle weakness,
numbness in the upper extremities,
bedridden for 2 months
Not fully recovered; gait instability,
headache, memory impairment
11 Female 70 Hypertension 5 days Bad mood for a short time, dizziness Not fully recovered; dizziness
12 Male 55 Hypertension, abdominal aortic
aneurysm
5 days Tremor in the upper extremities for 6
months
6 months
13 Male 34 No 5 days Anorexia and muscle weakness for 1
month, tremor in upper extremities,
bad mood for 5 months
5 months
14 Male 30 No 6 days Tremor of the upper extremities,
emotional instability, bad mood
1 year
15 Male 42 No 7 days Anorexia for 2 months, weight loss,
muscle weakness for 1 month, tremor
in upper extremities, bad mood
Not fully recovered; tremor
16 Male 25 No 5 days Headache 1 month
17 Male 23 No 6 days Headache 1 month
18 Male 70 Hypertension 9 days Weight loss, muscle weakness for 4–5
months, hearing loss, memory
impairment
Not fully recovered; hearing loss,
memory impairment
19 Male 86 Hypertension, diabetes, chronic
renal failure
7 days Severe muscle weakness, atrophy,
amnesia
Permanent impairment; bedridden,
dementia
20 Male 76 Hypertension, diabetes,
dyslipidemia
8 days Muscle weakness, anorexia for 1
month, weight loss, behavior disorder,
memory impairment, bad mood,
depression
Not fully recovered; major depression,
amnesia
21 Male 42 Hypertension, diabetes,
coronary disease
5 days Weight loss (8–10 kg), dizziness, bad
mood for 1 month, muscle weakness for
1 month
2 months
22 Male 80 Diabetes 6 days Weight loss, memory impairment,
hearing loss
Not fully recovered; memory
impairment, hearing loss
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83-year-old female patient with underlying disease recovered
completely in 10 months. Long-term residual effects are also
seen in non-neuroinvasive cases.14,25 Further studies areneeded to elucidate the factors that play a role in the severity
of the disease and the time to recovery.
Limitations of the present study were the small sample size and
the selection bias due to sampling of the patients from only one
A. Anastasiadou et al. / International Journal of Infectious Diseases 17 (2013) e494–e497 e497hospital. However, it was evident that during the outbreak in
Greece the ﬁndings in WNND patients were similar to those seen in
North America, suggesting that the pathogenicity to humans is
strain-related rather than lineage-related.
Since its emergence in Greece in 2010, WNV lineage 2 has
resulted in more than 250 neuroinvasive cases with increased
morbidity and mortality, and many of the patients are still
suffering from clinical and functional disabilities. Although the
epidemiology of WNV is unpredicted, the increasing spread of
lineage 2 strains might be of public health concern, and needs
further scientiﬁc attention. Public health measures are needed to
prevent the infection, especially in the elderly with underlying
diseases.
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